Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024)
Amylyx Pharmaceuticals (AMLX) posted Restructuring Costs of $22.9 million for Q2 2024.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024) Analysis & Trends
Amylyx Pharmaceuticals has reported Restructuring Costs for 1 years, with the latest figure at $22.9 million in Q2 2024.
- On a quarterly basis, Restructuring Costs changed N/A year-over-year to $22.9 million in Q2 2024; TTM through Jun 2025 was $22.9 million, a N/A change from a year earlier, with the FY2024 full-year figure at $22.9 million, changed N/A from the prior year.
- Restructuring Costs was $22.9 million for Q2 2024 at Amylyx Pharmaceuticals.
- The five-year high for Restructuring Costs was $22.9 million in Q2 2024, with the low at $22.9 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn |
| 10 | Amylyx Pharmaceuticals | 3.68 Bn | 3.68 Bn | - |